title: Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial.
abstract: To confirm the clinical usefulness of the measurement of urinary liver-type fatty acid-binding protein (L-FABP) in chronic kidney disease (CKD), we carried out a multicenter trial. Clinical markers were measured in patients with nondiabetic CKD (n = 48) every 1 to 2 months for a year. We divided patients retrospectively into progression (n = 32) and nonprogression (n = 16) groups on the basis of the rate of disease progression, then assessed several clinical markers. Initially creatinine clearance (Ccr) was similar in the 2 groups; however, the urinary L-FABP level was significantly higher in the former group than in the latter (111.5 vs 53 microg/g creatinine, P < .001). For the monitoring CKD, we set the cutoff values for urinary L-FABP and urinary protein at 17.4 microg/g creatinine and 1.0 g/g creatinine, respectively. Urinary L-FABP was more sensitive than urinary protein in predicting the progression of CKD (93.8% and 68.8%, respectively). However, urinary protein showed greater specificity than did urinary L-FABP (93.8% and 62.5%, respectively). Over time, the progression of CKD tended to correlate with changes in urinary L-FABP (r = - .32, P < .05), but not in urinary protein (r = .18, not significant). The dynamics of urinary protein differed from that of urinary L-FABP, which increased as Ccr declined. Urinary L-FABP is more sensitive than urinary protein in predicting the progression of CKD. Urinary excretion of L-FABP increases with the deterioration of kidney function. Urinary L-FABP is therefore a useful clinical marker in the monitoring of CKD.
authors.affiliation: Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
authors.forename: Atsuko
authors.initials: A
authors.lastname: Kamijo
authors.forename: Takeshi
authors.initials: T
authors.lastname: Sugaya
authors.forename: Akihisa
authors.initials: A
authors.lastname: Hikawa
authors.forename: Masaya
authors.initials: M
authors.lastname: Yamanouchi
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Hirata
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Ishimitsu
authors.forename: Atsushi
authors.initials: A
authors.lastname: Numabe
authors.forename: Masao
authors.initials: M
authors.lastname: Takagi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Hayakawa
authors.forename: Fumiko
authors.initials: F
authors.lastname: Tabei
authors.forename: Tokuichiro
authors.initials: T
authors.lastname: Sugimoto
authors.forename: Naofumi
authors.initials: N
authors.lastname: Mise
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Kimura
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000652:urine*; D002352:Carrier Proteins / Q000652:urine*; D002908:Chronic Disease; D018450:Disease Progression; D050556:Fatty Acid-Binding Proteins; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000175:diagnosis / Q000652:urine*; D008099:Liver / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010045:Outpatients
chemical_list: D015415:Biomarkers; D002352:Carrier Proteins; C493319:FABP1 protein, human; D050556:Fatty Acid-Binding Proteins